Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 1/20 | 0.49 |
| ▸ | FEN1 | P39748 | 2/20 | 0.42 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.42 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 6/20 | 0.40 |
| ▸ | FPR3 | P25089 | 1/20 | 0.40 |
| ▸ | FPR2 | P25090 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 2/20 | 0.40 |
| ▸ | CTSD | P07339 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 4/20 | 0.39 |
| ▸ | BCHE | P06276 | 2/20 | 0.39 |
| ▸ | GLS | O94925 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8511930 | 0.95 | SCN9A (0.42) | SCN9AFEN1ALOX5APGRM2FPR2 | |
| SCHEMBL8509456 | 0.92 | GRM2 (0.41) | SCN9AFEN1ALOX5APGRM2 | |
| SCHEMBL8509769 | 0.90 | GRM2 (0.41) | FEN1ALOX5APCHEK2GRM2FPR2 | |
| SCHEMBL9604241 | 0.87 | GRM2 (0.38) | SCN9AGRM2FPR2BACE1 | |
| SCHEMBL8509721 | 0.87 | GRM2 (0.38) | SCN9AGRM2FPR2BACE1 | |
| SCHEMBL8509437 | 0.87 | PDE4B (0.42) | SCN9AFEN1CHEK2GRM2 | |
| SCHEMBL9604227 | 0.85 | PDE8B (0.44) | FEN1ALOX5APGRM2FPR3FPR2 | |
| SCHEMBL9604226 | 0.85 | PDE8B (0.44) | FEN1ALOX5APGRM2FPR3FPR2 | |
| SCHEMBL8511774 | 0.82 | EPHX2 (0.39) | SCN9AGRM2 | |
| SCHEMBL9604240 | 0.82 | GRM2 (0.39) | GRM2FPR2BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785481-B2 | Ether benzotriazole derivatives | MERCK SHARP & DOHME CORP. (US) | 2014-07-22 | — | — | US | claimed |
| US-20120135977-A1 | ETHER BENZOTRIAZOLE DERIVATIVES | MERCK SHARP & DOHME LLC | 2012-05-31 | — | — | US | claimed |
| US-8785481-B2 | Ether benzotriazole derivatives | MERCK SHARP & DOHME CORP. (US) | 2014-07-22 | — | — | US | disclosed |
| US-8785481-B2 | Ether benzotriazole derivatives | MERCK SHARP & DOHME CORP. (US) | 2014-07-22 | — | — | US | disclosed |
| US-8785481-B2 | Ether benzotriazole derivatives | MERCK SHARP & DOHME CORP. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20120135977-A1 | ETHER BENZOTRIAZOLE DERIVATIVES | MERCK SHARP & DOHME LLC | 2012-05-31 | — | — | US | disclosed |
| US-20120135977-A1 | ETHER BENZOTRIAZOLE DERIVATIVES | MERCK SHARP & DOHME LLC | 2012-05-31 | — | — | US | disclosed |
| US-20120135977-A1 | ETHER BENZOTRIAZOLE DERIVATIVES | MERCK SHARP & DOHME LLC | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135977-A1 | ETHER BENZOTRIAZOLE DERIVATIVES | GRM2, GRIA2, GRIK2 | SCN9A 3983/4885FEN1 4631/4885ALOX5AP 1473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.